Parallax Volatility Advisers’s Vir Biotechnology VIR Stock Holding History

Parallax Volatility Advisers’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-45,000	Closed	-$1.1M	–	2644
2023 Q2	$1.1M	Hold	45,000	–	–	﹤0.01%	1367
2023 Q1	$1.05M	Buy	+45,000	New	+$1.15M	﹤0.01%	1484
2022 Q1	–	Sell	-400	Closed	-$17K	–	3453
2021 Q4	$17K	Buy	+400	New	+$15.7K	﹤0.01%	2801
2021 Q3	–	Sell	-70,000	Closed	-$3.31M	–	3425
2021 Q2	$3.31M	Buy	+70,000	New	+$3.18M	﹤0.01%	1433
2021 Q1	–	Sell	-34,400	Closed	-$921K	–	3677
2020 Q4	$921K	Buy	+34,400	New	+$1.12M	﹤0.01%	2213

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Parallax Volatility Advisers's VIR Position: Q2 2023 in Review

Parallax Volatility Advisers sold out of Vir Biotechnology (VIR) in Q2 2023, closing a stake of 4 shares — an estimated $100 sold.

Parallax Volatility Advisers first reported a position in VIR in Q4 2020 and held it in 3 quarters. The position peaked at $1.58M in Q4 2021. 226 funds tracked by Wall St. Rank hold VIR as of Q2 2023.

Parallax Volatility Advisers reported no remaining Vir Biotechnology position as of Q2 2023 after selling out during the quarter.
Parallax Volatility Advisers sold 4 Vir Biotechnology shares in Q2 2023, an estimated $100.
Parallax Volatility Advisers first reported a position in Vir Biotechnology in Q4 2020 and held it in 3 quarters.
Parallax Volatility Advisers's Vir Biotechnology position peaked at $1.58M in Q4 2021.
226 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2023.

Based on Parallax Volatility Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.